PMID- 32351702
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2055-0294 (Print)
IS  - 2055-0294 (Electronic)
IS  - 2055-0294 (Linking)
VI  - 6
DP  - 2020
TI  - Evaluation of the efficacy of drug treatment based on measurement of the 
      oxidative stress, using reactive oxygen metabolites and biological antioxidant 
      potential, in children with autism spectrum disorder and attention deficit 
      hyperactivity disorder.
PG  - 8
LID - 10.1186/s40780-020-00164-w [doi]
LID - 8
AB  - BACKGROUND: Autism spectrum disorder (ASD) is a neurodevelopmental disorder, 
      mainly characterized by impairment of social communication and restricted 
      interests. ASD is frequently accompanied by attention deficit hyperactivity 
      disorder (ADHD), which is characterized by carelessness, hyperactivity and 
      impulsivity (ASD/ADHD). It has been suggested that ASD and ADHD are associated 
      with oxidative stress, that is, that patients with ASD/ADHD are in a state of 
      increased oxidative stress. There are currenr tly no objective or biological test 
      criteria for evaluating the efficacy of drug therapy in these patients. The 
      purpose of this study was to evaluate whether oxidative stress markers [serum 
      reactive oxygen metabolites (d-ROMs) levels and biological antioxidant potential 
      (BAP)] can be used as objective indicators for evaluating the efficacy of drug 
      treatment in ASD/ADHD patients. METHODS: The subjects of this study subjects were 
      50 Japanese patients with ASD/ADHD aged 4 to 14 years old. Serum samples were 
      obtained from the patients to measure the serum levels of d-ROMs and the serum 
      BAP. The study subjects were divided into two age groups: preschool children (4 
      to 6 years old) and school-age children (7 to 14 years old), and the serum levels 
      of d-ROMs, serum BAP, serum BAP/d-ROMs ratio (hereinafter, the prefix serum will 
      be dropped), and scores on the Parent-interview ASD Rating Scales-Text Revision 
      (PARS-TR) and ADHD Rating Scale (ADHD-RS) were determined before and after drug 
      therapy and compared between the two groups. In addition, changes in the d-ROMs, 
      BAP and BAP/d-ROMs ratio and changes in the scores on the PARS-TR and ADHD-RS 
      after treatment were also analyzed. RESULTS: Significant decrease of the d-ROMs, 
      BAP, and scores on the PARS-TR and ADHD-RS, with a significant increase of the 
      BAP/d-ROMs ratio, was observed after treatment. In addition, a significant 
      correlation was observed between the changes in the d-ROMs and changes in the 
      scores on the PARS-TR and ADHD-RS after treatment in the school-age ASD/ADHD 
      children. CONCLUSION: Our results suggest the possibility that the serum level of 
      d-ROMs may be useful as an objective assessment marker to supplement the 
      subjective assessment of the effects of drug treatment in school-age children 
      with ASD/ADHD.
CI  - (c) The Author(s) 2020.
FAU - Kitaoka, Taisuke
AU  - Kitaoka T
AD  - 1Tokushima Bunri University, Graduate School of Pharmaceutical Sciences, 
      Nishihamahouji, Yamashiro-cho, Tokushima-shi, Tokushima, 770-8514 Japan. GRID: 
      grid.412769.f. ISNI: 0000 0001 0672 0015
FAU - Morimoto, Masahito
AU  - Morimoto M
AD  - Department of pharmacy, Japanese Red Cross Tokushima Hinomine Rehabilitation 
      Center for People with Disabilities, Shinbiraki, Chuden-cho, Komathushima-shi, 
      Tokushima, 773-0014 Japan.
FAU - Hashimoto, Toshiaki
AU  - Hashimoto T
AD  - Department of pediatrics, Japanese Red Cross Tokushima Hinomine Rehabilitation 
      Center for People with Disabilities, Shinbiraki, Chuden-cho, Komathushima-shi, 
      Tokushima, 773-0014 Japan.
FAU - Tsuda, Yoshimi
AU  - Tsuda Y
AD  - Department of pediatrics, Japanese Red Cross Tokushima Hinomine Rehabilitation 
      Center for People with Disabilities, Shinbiraki, Chuden-cho, Komathushima-shi, 
      Tokushima, 773-0014 Japan.
FAU - Nakatsu, Tadanori
AU  - Nakatsu T
AD  - Department of pediatrics, Japanese Red Cross Tokushima Hinomine Rehabilitation 
      Center for People with Disabilities, Shinbiraki, Chuden-cho, Komathushima-shi, 
      Tokushima, 773-0014 Japan.
FAU - Kyotani, Shojiro
AU  - Kyotani S
AD  - 1Tokushima Bunri University, Graduate School of Pharmaceutical Sciences, 
      Nishihamahouji, Yamashiro-cho, Tokushima-shi, Tokushima, 770-8514 Japan. GRID: 
      grid.412769.f. ISNI: 0000 0001 0672 0015
LA  - eng
PT  - Journal Article
DEP - 20200425
PL  - England
TA  - J Pharm Health Care Sci
JT  - Journal of pharmaceutical health care and sciences
JID - 101672177
PMC - PMC7183642
OTO - NOTNLM
OT  - Attention deficit hyperactivity disorder
OT  - Autism spectrum disorder
OT  - Objective assessment marker
OT  - Oxidative stress
OT  - Pediatrics
OT  - Reactive oxygen metabolites
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/05/01 06:00
MHDA- 2020/05/01 06:01
PMCR- 2020/04/25
CRDT- 2020/05/01 06:00
PHST- 2020/02/02 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/05/01 06:01 [medline]
PHST- 2020/04/25 00:00 [pmc-release]
AID - 164 [pii]
AID - 10.1186/s40780-020-00164-w [doi]
PST - epublish
SO  - J Pharm Health Care Sci. 2020 Apr 25;6:8. doi: 10.1186/s40780-020-00164-w. 
      eCollection 2020.